Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies

• Published in: Current heart failure reports Vol. 20; no. 1; pp. 56 - 62
• Main Authors: Tini, Giacomo, Tocci, Giuliano, Battistoni, Allegra, Sarocchi, Matteo, Pietrantoni, Camilla, Russo, Domitilla, Musumeci, Beatrice, Savoia, Carmine, Volpe, Massimo, Spallarossa, Paolo
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.02.2023
• Subjects: Cardiac Surgery; Cardiology; Cardiotoxicity; Cardiovascular Diseases - complications; Heart Failure - complications; Humans; Hypertension - complications; Imaging; Internal Medicine; Medicine; Medicine & Public Health; Radiology; Topical Collection on Cardio-Oncology; Vascular Surgery; Cardio-oncology; Arterial hypertension; Anti-VEGF; Cardiotoxicity; Anthracycline; Arterial hypertension-mediated organ damage
• ISSN: 1546-9530; 1546-9549
• DOI: 10.1007/s11897-023-00590-5

Purpose of the Review Arterial hypertension (AH) is the most common cardiovascular (CV) risk factor in the community and in oncologic patients. It also represents the most important CV condition predisposing to anticancer treatment-related cardiotoxicity. This risk is heightened in the presence of cardiac AH-mediated organ damage (HMOD). Influence of AH and HMOD on the development of cardiotoxicity will be reviewed, with a focus on specific scenarios and implications for management of oncologic patients. Recent Findings Not adequately controlled AH before or during anticancer treatments and/or development of AH during or after completion of such therapies have detrimental effects on the clinical course of oncologic patients, particularly if HMOD is present. Summary As overlooking CV health can jeopardize the success of anticancer treatments, the goal for clinicians caring for the oncologic patient should include the treatment of AH and HMOD.